County Durham & Tees Valley
Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on **Thursday 9th July 2020**

Classification of products:

G **Green drug** - Can be initiated and prescribed in all care settings O- Second line / alternative green drug

A **Amber Specialist initiation / recommendation drug**. Can be recommended by a specialist for initiation in primary care; or be initiated by a specialist and transferred to primary care once the patient stabilised. In some cases there may be a further restriction for use outlined - these will be defined in each case.

ASC **Amber Shared Care drug** - These are specialist drugs which must be initiated by the specialist, but with the potential to transfer to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care

R **Red drug** - Drugs that should remain under the total responsibility of the specialist. Usually considered as "hospital only" drugs

✕ **Not Approved** - Drugs that have been considered by the APC or other approved body and are not approved for prescribing within County Durham & Darlington.

Not Reviewed - Drugs that haven't been reviewed by the APC yet. This usually means that no application has been received or that an application is in progress. These drugs are not normally considered appropriate for prescribing in County Durham & Darlington.

Unclassed Drug - Drugs that do not fall into one of the above categories

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meetings				
None				
2) New Requests				
None				
3) New formulations & extensions to use				
None				
5) Products considered by NICE				
TA622: Sotagliflozin with insulin for treating type 1 diabetes			✓	The formulary will reflect the TAG – CCG is the responsible commissioner. No further action for APC at this stage as not yet launched in the UK. Launch planned for 2020. Launch will be highlighted in future horizon scanning.
TA623: Patiromer for treating hyperkalaemia – acute lifethreatening hyperkalaemia	✓ R			The formulary will reflect the TAG – CCG is the responsible commissioner.
TA623: Patiromer for treating hyperkalaemia – persistent hyperkalaemia	✓ A			The formulary will reflect the TAG – CCG is the responsible commissioner.

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
TA624: Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA625: Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal)		✓		The formulary will reflect the TAG – NHS England is the responsible commissioner (NICE unable to make a recommendation)
TA627: Lenalidomide with rituximab for previously treated follicular lymphoma	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA630: Larotrectinib for treating NTRK fusion-positive solid tumours	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
7) Appeals against earlier decisions by the APC				
None				
8) Products considered by NTAG				
Voke® Inhaler Nicotine Replacement Therapy for Smoking Cessation		✓		The formulary will reflect the NTAG recommendation. **Decision:** The Northern (NHS) Treatment Advisory Group does not recommend the use of Voke® Inhaler as a stop smoking aid on the NHS or for prescribing by GPs.
Vaginal devices for female urinary stress incontinence		✓		The formulary will reflect the NTAG recommendation. **Decision:** The Northern (NHS) Treatment Advisory Group does not recommend the use of Vaginal devices (e.g. Diveen®, Contiform® and Efemia®) for the management of female urinary stress incontinence on the NHS. Should patients wish to use these devices they can be purchased over the counter for occasional use, for example during exercise
Purewick® female external urinary catheter		✓		The formulary will reflect the NTAG recommendation. **Decision:** The Northern (NHS) Treatment Advisory Group does not recommend the use of Purewick® female external urinary catheter for the management of female urinary incontinence
Verteporfin (Visudyne®) with photo-dynamic therapy for chronic central serous chorioretinopathy	✓ R			**The formulary will reflect the NTAG recommendation.** **Decision:** The Northern (NHS) Treatment Advisory Group recommends the use of Verteporfin (Visudyne®) with photo-dynamic therapy (PDT) outside of its product license for the treatment of chronic CSCR.

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
Infliximab Subcutaneous (Remsima®)	✓ R			The formulary will reflect the NTAG recommendation. **Decision:** The Northern (NHS) Treatment Advisory Group recommends Remsima SC® be available as additional treatment option during the COVID-19 pandemic for both licensed and off-label uses as part individual hospital Trust management strategies to reduce hospital day case admissions, and keep immunosuppressed people out of hospital during the COVID-19 pandemic. Remsima SC® could be considered as an option where the patient would otherwise get the intravenous Remsima® formulation of Infliximab. This recommendation is subject to any off-label use of Remsima SC® being considered and approved via individual hospital trust governance processes (including clinical governance) for the use of unlicensed/off-label drugs. It was also agreed that this recommendation would be reviewed after 12 months.
8) Miscellaneous decisions by the APC				
Flubiprofen tablets		✓		**Decision:** Removed from formulary as never used for ophthalmology indications.
Remdesivir infusion for confirmed COVID-19 infected patients	✓ R			**Decision:** Approved for the treatment of coronavirus (COVID-19) as per national DHSC commissioning policy for remdesivir in the treatment of COVID-19.
Triptorelin 22.5mg (Decapetyl SR®) Injection for precocious puberty	✓ A			**Decision:** Add to formulary as AMBER Specialist Initiation as per other formulations of triptorelin for precocious puberty.

The following guidelines were presented to and approved at the July 2020 meeting of the APC:

- CD&T APC Anticoagulation during Covid-19 - approved 24.4.2020 via Chair's Action
- CD&T APC Adult Asthma Guidelines – reviewed & updated
- CD&T APC Paediatric Asthma Guidelines – reviewed & updated
- CD&T APC COPD Guidelines – reviewed & updated

The following shared care guidelines were presented to and approved at the July 2020 meeting of the APC:

- Nil

Other documents presented to and approved at the July 2020 meeting of the APC:

- CD&T APC Terms of Reference – updated.
- CD& APC Annual Report 2019/2020
- APC memo – position of the NHSE proposal for DOAC procurement during Covid-19 - approved previously via Chair's Action